The price of Johnson & Johnson (NYSE:JNJ) shares last traded on Wall Street rose 2.31% to $157.47.
JNJ stock price is now -1.37% away from the 50-day moving average and 0.46% away from the 200-day moving average. The market capitalization of the company currently stands at $379.48B.
On November 15, 2024, Wolfe Research recently initiated its ‘Outperform’ rating on the stock quoting a target price of $190, while ‘Daiwa Securities’ rates the stock as ‘Neutral’
In other news, Decker Robert J, VP Corporate Controller sold 6,999 shares of the company’s stock on Feb 25 ’25. The stock was sold for $1,160,994 at an average price of $165.88. Upon completion of the transaction, the VP Corporate Controller now directly owns 21,001 shares in the company, valued at $3.31 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 25 ’25, Officer Decker Robert J bought 6,999 shares of the business’s stock. A total of $1,161,010 was incurred on buying the stock at an average price of $165.88. A total of 0.13% of the company’s stock is owned by insiders.
During the past 12 months, Johnson & Johnson has had a low of $140.68 and a high of $169.99. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 1.11, and a quick ratio of 0.86. According to the stock market information, the enterprise value for the company is $392439398400, which is based on a 17.50 price-to-earnings ratio, a 3.09 price-to-earnings-growth ratio, and a beta of 0.43. The fifty day moving average price for JNJ is $159.6642 and a two-hundred day moving average price translates $156.74525 for the stock.
The latest earnings results from Johnson & Johnson (NYSE: JNJ) was released for 2025-03-30. The net profit margin was 24.42% and return on equity was 20.06% for JNJ. The company reported revenue of $21.89 billion for the quarter, compared to $21.38 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.39 percent.
